The identification of immune checkpoint molecules has provided a theoretical basis for the development of immunotherapy for HCC, such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) (14). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.